These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22048815)

  • 1. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
    Weigman VJ; Chao HH; Shabalin AA; He X; Parker JS; Nordgard SH; Grushko T; Huo D; Nwachukwu C; Nobel A; Kristensen VN; Børresen-Dale AL; Olopade OI; Perou CM
    Breast Cancer Res Treat; 2012 Jun; 133(3):865-80. PubMed ID: 22048815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer.
    Chao HH; He X; Parker JS; Zhao W; Perou CM
    PLoS One; 2012; 7(12):e51719. PubMed ID: 23284754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
    Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INPP4B and RAD50 have an interactive effect on survival after breast cancer.
    Dai X; Fagerholm R; Khan S; Blomqvist C; Nevanlinna H
    Breast Cancer Res Treat; 2015 Jan; 149(2):363-71. PubMed ID: 25528023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
    PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
    Joosse SA; Brandwijk KI; Mulder L; Wesseling J; Hannemann J; Nederlof PM
    Genes Chromosomes Cancer; 2011 Feb; 50(2):71-81. PubMed ID: 21104783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
    Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM
    Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
    Li D; Xia H; Li ZY; Hua L; Li L
    Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
    Natrajan R; Weigelt B; Mackay A; Geyer FC; Grigoriadis A; Tan DS; Jones C; Lord CJ; Vatcheva R; Rodriguez-Pinilla SM; Palacios J; Ashworth A; Reis-Filho JS
    Breast Cancer Res Treat; 2010 Jun; 121(3):575-89. PubMed ID: 19688261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.
    Bartkova J; Tommiska J; Oplustilova L; Aaltonen K; Tamminen A; Heikkinen T; Mistrik M; Aittomäki K; Blomqvist C; Heikkilä P; Lukas J; Nevanlinna H; Bartek J
    Mol Oncol; 2008 Dec; 2(4):296-316. PubMed ID: 19383352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.
    Lin Y; Lin S; Watson M; Trinkaus KM; Kuo S; Naughton MJ; Weilbaecher K; Fleming TP; Aft RL
    Breast Cancer Res Treat; 2010 Oct; 123(3):691-9. PubMed ID: 19967557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
    Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
    Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
    Chen X; Theobard R; Zhang J; Dai X
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31872854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast tumor copy number aberration phenotypes and genomic instability.
    Fridlyand J; Snijders AM; Ylstra B; Li H; Olshen A; Segraves R; Dairkee S; Tokuyasu T; Ljung BM; Jain AN; McLennan J; Ziegler J; Chin K; Devries S; Feiler H; Gray JW; Waldman F; Pinkel D; Albertson DG
    BMC Cancer; 2006 Apr; 6():96. PubMed ID: 16620391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.